New asthma drug passes first safety hurdle in small trial

NCT ID NCT05366764

Completed Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested the safety and tolerability of a new drug called SAR443765 in 36 people, including healthy volunteers and those with mild-to-moderate asthma. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. The goal was to see if the drug is safe enough for further testing, not to measure its effectiveness against asthma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR443765 (an injectable drug)
What this could lead to: If successful, this could point toward a new treatment option for asthma that helps control symptoms.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Investigational Site Number : 2760001

Berlin, Germany
Investigational Site Number : 8260001

Belfast, BT9 6AD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.